ASX announcements

Date	Title
03/12/2018	Chinese Patent for Biomarkers to Monitor Disease Progression for Stem Cell Therapy
22/11/2018	Results of Annual General Meeting
22/11/2018	CEO Presentation to 2018 Annual General Meeting
22/11/2018	Chairman's Address to Shareholders
31/10/2018	Regeneus to present at AusBiotech 2018 - Australia's Life Sciences Conference
19/10/2018	Notice of Annual General Meeting 22 November 2018 and Explanatory Statement
18/10/2018	Progenza - European Patent Office issues Notice of Intention to Grant European Patent
19/09/2018	Appendix 3Y - Change of Director's Interest Notice
18/09/2018	Notice on Annual General Meeting
06/09/2018	Regeneus receives R and D tax incentive of $2.4m
30/08/2018	Appendix 4G and Corporate Governance Statement
30/08/2018	Regeneus - FY18 Results and Business Update Presentation
30/08/2018	Regeneus 2018 Full-Year Results and Business Update
30/07/2018	Positive clinical trial results for cancer vaccine
25/07/2018	Price Query - Response to ASX
10/07/2018	Regeneus announces United States Patent Office decision to allow patent for Progenza
03/07/2018	Update on licensing Progenza in Japan
29/06/2018	R and D loan facility approved - ASX listing rule waiver
03/05/2018	Appendix 3Y Change of Director's Interest Notice
07/03/2018	Positive trial results of Progenza for knee osteoarthritis
20/02/2018	Regeneus Presentation on Half Year Results FY18
20/02/2018	Regeneus 2018 Half-Year Results and Business Update
14/02/2018	Progenza granted Advanced Therapy Medicinal Product designation by European Medicines Agency
12/02/2018	Japanese Patent Office to grant patent for cancer vaccine technology
06/02/2018	Regeneus Announces Successful Results in Acne Study